Literature DB >> 24176448

Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.

Akshay Bagai1, Paul W Armstrong, Amanda Stebbins, Kenneth W Mahaffey, Judith S Hochman, W Douglas Weaver, Manesh R Patel, Christopher B Granger, Renato D Lopes.   

Abstract

BACKGROUND: Left ventricular end-diastolic pressure (LVEDP) is frequently measured during primary percutaneous coronary intervention (PCI). However, little is known of this measurement's utility in predicting outcomes or informing treatment decisions. We sought to determine the prognostic value of LVEDP measured during primary PCI for ST-segment elevation myocardial infarction (STEMI).
METHODS: We studied 1,909 (33.2%) of 5,745 STEMI patients in whom LVEDP was measured during primary PCI in the APEX-AMI trial. Cox regression analysis was used to evaluate whether LVEDP was an independent predictor of mortality and the composite of death, cardiogenic shock, or congestive heart failure (CHF) at 90 days.
RESULTS: The median (25th, 75th percentiles) LVEDP level was 22 mm Hg (16, 29); compared with patients with LVEDP ≤ 22 mm Hg, those with LVEDP > 22 mm Hg had higher rates of CHF (7.3% vs 3.1%, P < .001), cardiogenic shock (4.6% vs 1.7%, P < .001), and death (4.1% vs 2.2%, P = .014) at 90 days. After multivariable adjustment, LVEDP was associated with increased risk of mortality through 90 days (adjusted hazard ratio 1.22, 95% CI 1.02-1.46, per 5-mmHg increase, P = .044) and the composite of death, cardiogenic shock, or CHF within the first 2 days (adjusted hazard ratio 1.40, 95% CI 1.23-1.59, per 5-mm Hg increase, P < .001), but not from day 3 to 90 (P = .25).
CONCLUSIONS: Left ventricular end-diastolic pressure measured during primary PCI for STEMI is an independent predictor of inhospital and longer term cardiovascular outcomes. Measuring LVEDP may be useful to stratify patient risk and guide postinfarct treatment.
© 2013.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24176448     DOI: 10.1016/j.ahj.2013.08.006

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  16 in total

1.  Combined assessment of left ventricular end-diastolic pressure and ejection fraction by left ventriculography predicts long-term outcomes of patients with ST-segment elevation myocardial infarction.

Authors:  Daiga Saito; Rine Nakanishi; Ippei Watanabe; Takayuki Yabe; Ryo Okubo; Hideo Amano; Mikihito Toda; Takanori Ikeda
Journal:  Heart Vessels       Date:  2017-11-15       Impact factor: 2.037

2.  A novel anti-TNF scFv constructed with human antibody frameworks and antagonistic peptides.

Authors:  Shusheng Geng; Hong Chang; Weisong Qin; Ming Lv; Yan Li; Jiannan Feng; Beifen Shen
Journal:  Immunol Res       Date:  2015-07       Impact factor: 2.829

3.  Left ventricular end-diastolic pressure-guided hydration for the prevention of contrast-induced acute kidney injury in patients with stable ischemic heart disease: the LAKESIDE trial.

Authors:  Armin Marashizadeh; Hamid Reza Sanati; Parham Sadeghipour; Mohamad Mehdi Peighambari; Jamal Moosavi; Omid Shafe; Ata Firouzi; Ali Zahedmehr; Mohsen Maadani; Farshad Shakerian; Reza Kiani; Bahram Mohebbi; Mohammad Javad Alemzadeh-Ansari; Reza Tahvili; Batoul Naghavi
Journal:  Int Urol Nephrol       Date:  2019-07-22       Impact factor: 2.370

4.  CineCT platform for in vivo and ex vivo measurement of 3D high resolution Lagrangian strains in the left ventricle following myocardial infarction and intramyocardial delivery of theranostic hydrogel.

Authors:  D E Midgett; S L Thorn; S S Ahn; S Uman; R Avendano; I Melvinsdottir; T Lysyy; J S Kim; J S Duncan; J D Humphrey; X Papademetris; J A Burdick; A J Sinusas
Journal:  J Mol Cell Cardiol       Date:  2022-02-25       Impact factor: 5.763

5.  Prognostic Value of LVEDP in Acute Myocardial Infarction: a Systematic Review and Meta-Analysis.

Authors:  Stephen C Brienesse; Allan J Davies; Arshad Khan; Andrew J Boyle
Journal:  J Cardiovasc Transl Res       Date:  2017-12-14       Impact factor: 4.132

6.  Left Ventricular Pressure Ratio Predicts In-Hospital Outcomes in Hospitalized Heart Failure With Reduced Ejection Fraction.

Authors:  Sameh W Almousa; Mark N Belkin; Tess Allan; Allison Stephens; Joseph Kern; Miryea Cisneros; Janet Friant; Cynthia Arevalo; Sandeep Nathan; Atman P Shah; Jonathan Paul; Rohan Kalathiya; Jonathan Grinstein; John E A Blair
Journal:  J Invasive Cardiol       Date:  2021-06-16       Impact factor: 2.022

7.  Natural history and prognostic implications of left ventricular end-diastolic pressure in reperfused ST-segment elevation myocardial infarction: an analysis of the thrombolysis in myocardial infarction (TIMI) II randomized controlled trial.

Authors:  Arshad A Khan; Mohammed S Al-Omary; Nicholas J Collins; John Attia; Andrew J Boyle
Journal:  BMC Cardiovasc Disord       Date:  2021-05-17       Impact factor: 2.298

8.  The N-terminal propeptide of type III procollagen in patients with acute coronary syndrome: a link between left ventricular end-diastolic pressure and cardiovascular events.

Authors:  Cheng-Hung Lee; Wen-Chen Lee; Shang-Hung Chang; Ming-Shien Wen; Kuo-Chun Hung
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

9.  Aortic Pulsatility Index: A Novel Hemodynamic Variable for Evaluation of Decompensated Heart Failure.

Authors:  Mark N Belkin; Sara Kalantari; Anthony J Kanelidis; Tamari Miller; Bryan A Smith; Stephanie A Besser; David Tehrani; Ben B Chung; Ann Nguyen; Nitasha Sarswat; John E A Blair; Daniel Burkhoff; Gabriel Sayer; Sean P Pinney; Nir Uriel; Gene Kim; Jonathan Grinstein
Journal:  J Card Fail       Date:  2021-05-25       Impact factor: 6.592

10.  Usefulness of a Novel Risk Score to Predict In-Hospital Mortality in Patients ≥ 60 Years of Age with ST Elevation Myocardial Infarction.

Authors:  Lorena Millo; Alexander McKenzie; Andrew De la Paz; Cynthia Zhou; Michael Yeung; George A Stouffer
Journal:  Am J Cardiol       Date:  2021-07-12       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.